Evidence map›Paper›PMID 41449347›Full record

ArticleBMC microbiology2025

Comparative analysis of drug susceptibility among different Mycobacterium abscessus morphotypes.

Kai Cheng, Jiaying Guo, Yuanyuan Shang, Weicong Ren, Weijie Zhao, Shanshan Li

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kai Cheng *Department of Pharmacy, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, P. R. China.
Jiaying Guo *Department of Bacteriology and Immunology, Beijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 9, Beiguan Street, Tongzhou District, Beijing, 101149, P. R. China.
Yuanyuan ShangDepartment of Bacteriology and Immunology, Beijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 9, Beiguan Street, Tongzhou District, Beijing, 101149, P. R. China.
Weicong RenDepartment of Bacteriology and Immunology, Beijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 9, Beiguan Street, Tongzhou District, Beijing, 101149, P. R. China.
Weijie ZhaoDrug Clinical Trial Research Institution Office, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis & Thoracic Tumor Research Institute, No. 9, Beiguan Street, Tongzhou District, Beijing, 101149, P. R. China. zhaoweijie415@163.com.
Shanshan LiDepartment of Bacteriology and Immunology, Beijing Key Laboratory for Key Technologies in Tuberculosis Prevention and Control, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 9, Beiguan Street, Tongzhou District, Beijing, 101149, P. R. China. lss9011@126.com.

Funding

Beijing Municipal Science & Technology Commission Z221100007422056Beijing Nova Program 20230484295
6 · The paper itself

Abstract

backgroundMycobacterium abscessus (MAB), a rapidly growing non-tuberculous mycobacterium, presents severe therapeutic challenges due to its intrinsic and acquired multidrug resistance. Notably, MAB exhibits phenotypic heterogeneity, with smooth (S) and rough (R) morphotypes displaying distinct drug susceptibility phenotypes.

resultsWe systematically examined the phenotypic diversity and drug susceptibility profiles of 100 clinical MAB isolates, including 79 R-type, 13 S-type, and 8 mixed (M) morphotypes. The three morphotypes (R, S, M) exhibited distinct drug resistance profiles. Both R-type and S-type strains showed broad-spectrum resistance to fluoroquinolones, tetracycline derivatives, and carbapenems. In contrast, S-type strains remained fully susceptible to clofazimine (CFZ), linezolid (LNZ), and trimethoprim-sulfamethoxazole (TMS). Notably, significant differences in resistance to capreomycin (CAP) and clofazimine (CFZ) were observed among the three morphotypes. Genotypic analysis revealed a homogeneous distribution of key resistance genes (erm(41), rrl, rrs) across morphotypes.

conclusionsOur findings highlight the relationship between MAB morphotypes and antibiotic resistance is complex and drug specific. It is necessary to integrate morphotype with genotypic profiling and phenotypic characterization to better understand the complex resistance landscape of MAB and to guide more effective therapeutic strategy.

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialMycobacterium abscessusClofazimineFluoroquinolonesGenotypeHumansMicrobial Sensitivity TestsMycobacterium Infections, NontuberculousPhenotypeAnti-Bacterial AgentsClofazimineFluoroquinolonesChemotherapyClofazimineDrug resistanceMorphotypesMycobacterium abscessus

Identifiers

PMID41449347
PMCPMC12882414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.